PharmaVoice ١٢ فبراير ٢٠٢٦ Lilly’s $2.4B bet on off-the-shelf cell therapy is part of a wider Big Pharma shift
PharmaVoice ٢٩ يناير ٢٠٢٦ Eli Lilly, BioAge chase NLRP3 inhibitors with ‘pipeline in a pill’ potential
PharmaVoice ١٤ يناير ٢٠٢٦ Lilly, Novo test direct-to-employer approach that could cut out PBMs and lower costs
PharmaVoice ٢٤ نوفمبر ٢٠٢٥ Eli Lilly becomes first drugmaker to hit $1 trillion in market value #Eli Lilly #drugmaking peers